Mumbai, April 7 -- The drug, available in 40 mg tablets, is approved as a new treatment for adults with erosive esophagitis of all grades. FEXUCLUE, containing Fexuprazan, is primarily used to treat acid-related disorders, including gastroesophageal reflux disease (GERD) and erosive esophagitis. It is also being studied for the prevention of NSAID-induced peptic ulcers and gastritis.

Sun Pharma has obtained the rights from Daewoong Pharmaceutical, a South Korean biopharmaceutical company, to manufacture and commercialize FEXUCLUE in India. As part of the agreement, Daewoong will receive upfront and milestone payments, as well as royalties.

Kirti Ganorkar, CEO of India Business, Sun Pharma, said, "Erosive esophagitis is a serious conditi...